StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ELTXBullishEarningsnews
High materiality7/10

Elicio to Start Phase 1 ELI-002 7P Combo in Q4 2026 for Metastatic PDAC

Aug 13, 2026, 4:11 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term catalysts (Phase 1 start in Q4 2026, plus new neoadjuvant trial) and improved balance sheet reduce dilution risk, potentially triggering upside if early activity signals are favorable; however, a Phase 2 miss historically tempers upside.

AI summary

What happened, with direct paths to the underlying reporting

Elicio plans a Phase 1 study of ELI-002 7P in combination with a RAS inhibitor, with or without anti-PD-1, in metastatic PDAC beginning in Q4 2026. Phase 2 AMPLIFY-7P missed the primary endpoint, but subgroups and a new MSK-led neoadjuvant trial support continued development; a $15M financing extends cash into 2027, underpinning near-term progress.

  • ELTX to initiate Phase 1 ELI-002 7P combo with/without a RAS inhibitor.
  • AMPLIFY-7P Phase 2 did not meet primary endpoint; subgroups guiding Phase 3.
  • MSK-led neoadjuvant trial activated for ELI-002 7P with chemo and anti-PD-1.
  • Recent $15M financing strengthens balance sheet; runway into Q1 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event